Researchers identified ANKRD11 as a key regulator that suppresses CD8+ T cell activity during chronic hepatitis B virus infection and cancer. ANKRD11 deficiency reprograms CD8+ T cell differentiation to enhance immunity in chronic infection and cancer, making it a potential therapeutic target.
Researchers at Cold Spring Harbor Laboratory used machine learning concepts to study the immune system's learning process, finding that the system achieves negative selection through generalization. This process allows for the correct deletion of self-reactive T cells despite encountering only a small fraction of the body's self-peptides.
Researchers are developing a novel smart coating to enable continuous monitoring of cells during CAR T-cell production, reducing production costs. The biosensor coating is expected to reduce human errors and costs associated with existing flow cytometry methods.
Research suggests that consuming high levels of sucralose can make cancer treatment less effective by disrupting the gut microbiome and altering T cell function. However, adding arginine or citrulline supplements to the diet may restore immunotherapy effectiveness in patients with melanoma and non-small cell lung cancer.
Researchers discovered a way to boost T cells' ability to fight cancer by rewiring their energy metabolism. By blocking Ant2 protein, they created a state of heightened readiness and potency in T cells, leading to greater stamina, faster replication, and sharper targeting of cancerous threats.
A new study from the University of Pittsburgh shows exercise improves cancer outcomes and enhances response to immunotherapy in mice by reshaping the gut microbiome. The research found that a specific compound called formate, produced by gut bacteria in exercised mice, was associated with better outcomes in patients with melanoma.
Scientists have modified mRNA vaccines to include the cytokine IL-12, enhancing T cell responses and improving protection against diseases such as SARS-CoV-2, influenza, melanoma, and listeria infection. The study's findings suggest a promising approach to enhance immune stimulation against cancer and other pathogens.
AIC100 demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer, including anaplastic thyroid cancer (ATC) and relapsed/refractory poorly differentiated thyroid cancer (PTDC). The therapy showed significant tumor shrinkage and disease control in 56% of patients.
The collaboration enables point-of-care assays that simplify the analysis of T-cell responses, providing rapid results for doctors and researchers. This technology has been successfully applied in various research studies, including those on Hepatitis B Virus and SARS-CoV-2 infections.
Researchers at MD Anderson Cancer Center made several key discoveries, including the spatial organization of cancer-associated fibroblasts across various cancers and a study on treatment resistance in SMARCA4-mutant lung cancer. These findings highlight the importance of investigating cell populations in their spatial context to better...
Research from the University of Chicago shows that a specially trained population of immune cells, called peacekeeper cells, prevents other immune cells from attacking their own cells during infection. This specificity allows the immune system to distinguish between foreign and self-antigens, preventing autoimmune attacks.
La Jolla Institute scientists found that a protein in brain cells drives Parkinson's onset and may explain why the disease is more common in men. PINK1 appears to mark brain cells for immune cell attack, leading to inflammation and death.
A new study led by La Jolla Institute for Immunology scientists found that children who experience multiple dengue virus infections develop protective T cells, which help fight the virus. These T cells appear to be key to dengue virus immunity and may inform the development of a vaccine that prompts a similar response.
Concordia researchers propose a novel method using ultrasound-guided microbubbles to stimulate critical cytokine secretion in T cells, potentially re-activating them and increasing the release of proteins needed to fight cancer. The approach could complement existing treatments and improve outcomes.
Scientists discovered that T cells can prevent acute viral infections, challenging traditional views on sterilising immunity and herd immunity. The study found that T cells controlled viral loads and antibodies produced, and were effective in preventing infection to undetectable levels in some participants.
Researchers discovered a key role for neutrophils in cancer cell colonization of abdominal fat through the release of DNA webs called NETs. Additionally, a new biomarker study found that dose-dense chemotherapy improved disease-free survival by 20% and overall survival by 15% for women with early-stage ER-positive breast cancer.
A new study by La Jolla Institute for Immunology researchers suggests that many people may already have immune cells on standby to combat the H5N1 virus. The study found similarities between H5N1 and seasonal influenza viruses, allowing scientists to predict cross-reactive T cell responses that could help decrease disease severity.
Researchers at Gladstone Institutes and UCSF identified MED12 as a crucial switch that regulates T cell rest and activation. The study found that MED12 promotes rest in resting cells and activation in activated cells, and its removal led to blurred lines between rest and activation.
Research suggests that T-cell receptor repertoire analysis can inform treatment responses and predict efficacy in combination therapies for HCC. Advances in sequencing technologies are refining our understanding of tumor-immune interactions and adaptive immune mechanisms.
New research from the University of Pittsburgh found that opioids can suppress the immune system and reduce the effectiveness of immunotherapy for head and neck cancer. However, peripherally restricted OPRM1 antagonists (PAMORAs) may block opioid-induced immunosuppression and improve response rates to immune checkpoint inhibitor therapy.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with advanced small cell bladder cancer and small cell/neuroendocrine prostate cancer. The study found that the combination treatment resul...
Researchers at the University of Pittsburgh found that blocking the uptake of lactic acid, a key factor in T cell exhaustion, can reinvigorate these cells. This new approach shows promise for improving tumor control and treatment outcomes in various cancers.
Researchers at Saint Louis University School of Medicine investigated T-cell responses between male and female patients with lung cancer. They found that a protein called CXCL13 is more highly expressed in females than males, indicating a better marker of immunotherapy response in females.
Researchers at MIT found that a two-dose schedule for an HIV vaccine can generate a strong response to the virus, outperforming a traditional seven-dose regimen. The first dose primes the immune system, helping it to produce antibodies more effectively when a larger dose is administered one week later.
Researchers highlight key phagocytosis checkpoints and 'do not eat me' signals as potential therapeutic targets for novel immunotherapies. The editorial summarizes challenges in targeting CD47 and potential solutions to overcome these obstacles.
Scientists discovered that T follicular helper cells indirectly control the anti-influenza response, leading to less effective immunity. The study found that the current flu vaccine formulation could be improved by excluding internal proteins and targeting surface proteins.
Researchers uncovered how combining immunotherapies targeting PD1 and LAG3 enhances CD8+ T cell responses, leading to improved cancer-killing prowess and enhanced survival rates. The studies also revealed that relatlimab is not inert and can be combined with other immunotherapies to improve responses.
Researchers developed a lipid nanoparticle formulated miR-193a-3p mimic that enhances T cell mediated immune responses and induces immunogenic cell death in tumors. This study demonstrates the potential of this therapy to prolong animal survival and reduce metastasis, offering new hope for cancer treatment.
Researchers at La Jolla Institute for Immunology have discovered immune cells, such as tissue resident memory cells, in the upper airway that can fight infections and build long-term immunity. These findings may lead to better vaccines and a deeper understanding of immunity against respiratory pathogens.
A new study sheds light on fatty liver disease MASH's pathology, revealing T cell activation and growth in response to poor diet. The research holds promise for developing a biomarker test to track disease progression before it's at a late stage.
A new study has found that 90-95% of participants produced strong T-cell responses after exposure to adenoviral vaccines in a lab setting. This unexpected finding may have implications for the effectiveness and safety of future COVID-19 vaccines, as well as other infectious diseases.
Researchers identified two distinct T-cell signatures in children with newly diagnosed type 1 diabetes and those at risk of developing the disease. These signatures may serve as potential biomarkers and targets for preventive immunotherapy treatments.
Researchers describe redundant innate immune pathways triggered by AAV vectors, including sensing of viral genome and cytoplasmic DNA sensors. The study highlights the need to understand complex biologic mechanisms underlying adverse reactions to AAV vectors in human gene therapy trials.
Researchers have identified a novel type of T cell that can recognize and respond to multiple bacterial strains in the gut. This breakthrough finding has significant implications for treating diseases such as cancer and inflammatory bowel disease. The discovery was made by Kazuki Nagashima, winner of the NOSTER & Science Microbiome Prize.
Researchers at the University of Houston have identified a subset of T cells called CD8-fit that show high motility and serial killing capabilities in patients with clinical responses. These cells were discovered using a patented approach called TIMING, which evaluates cell behavior and movement to identify potential cancer-killing cells.
A Cleveland Clinic-led team of scientists discovered that protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and resist treatment. The interaction between VISTA and a newly discovered inhibitory receptor LRIG1 suppresses T cell replication, survival, and function.
Researchers found that abnormally active B cell metabolism causes an inflammatory immune response in individuals with Multiple Sclerosis (MS), leading to nerve damage and symptoms. Emerging BTK inhibitors alter this abnormal B cell respiration, stopping the signaling that leads to MS flare-ups.
University of Minnesota researchers found that immunotherapy improves CD8+ T-cell responses in older mice, reducing mortality from infections. The treatment, PD1 blockade, enhances the ability of T cells to kill harmful cells infected with a virus.
Researchers found that T cells and memory B cells provide durable protection against symptomatic SARS-CoV-2 infection, with levels attainable after two doses of mRNA vaccination. The study suggests a two-dose vaccination regimen for children against COVID-19.
Researchers at the University of Leipzig Medical Center have identified biomarkers associated with the response to CAR T cell therapy in multiple myeloma. These biomarkers enable patients to predict their likelihood of responding well or less well to treatment before initiating therapy.
Researchers at TUM have uncovered a mechanism by which tumor cells prevent the formation of immune responses, including cytotoxic T cells. This discovery provides rationales for new cancer immunotherapies and could enhance existing treatments.
A new study developed two machine learning models to quantify CD8+ cell positivity and classify the immunophenotype of cancer specimens in patients with non-small cell lung cancer. The models hold promise for identifying patients who may benefit from immunotherapy.
Tetracycline antibiotics have been found to enhance the antitumor activity of T lymphocytes by targeting galactin-1, an immunosuppressive protein produced by cancer cells. This breakthrough discovery may lead to the development of new drugs that target different immune pathways and benefit patients with cancer.
Researchers identify a promising strategy for combating hepatitis B virus (HBV) by boosting the effects of immune cells called stem cell memory T cells (TSCMs). In a mouse model, introducing TSCMs from patients into mice resulted in the elimination of HBV-infected liver cells.
A new study from Johns Hopkins Medicine found that circulating tumor DNA levels can accurately assess how gastroesophageal cancers respond to treatment and predict future prognosis. The study tracked minimal residual disease by analyzing ctDNA, showing a correlation between ctDNA clearance and cancer-free survival.
A new DNA origami platform, DoriVac, enables precise spacing of adjuvant molecules and a variety of antigens to enhance anti-tumor responses. The vaccine demonstrated enhanced efficacy in controlling tumor growth and prolonging survival in mice, synergizing with immune checkpoint inhibitors.
Researchers have identified a subset of T-cells that acts like stem cells and continuously generates effector T-cells that attack transplanted organs. Targeting the transcription factor IRF4 may lead to innovative therapies for patients with chronic infections, cancers, autoimmune diseases and transplanted organs.
Researchers found that T cells can reshape their memory and maintain diversity against COVID-19 variants in response to successive mRNA vaccinations. The study revealed a shift among clonotypes, with a change from early responders to main responders after the second shot, suggesting a new dominant population of effector-memory T cells.
Scientists from the La Jolla Institute for Immunology found that patients with 'cold' tumors produce cancer-fighting T cells, suggesting a potential cure from within. The researchers developed an approach called 'Identify, Predict, Validate' to detect these T cells in over 130 patients.
A new off-the-shelf vaccine has shown promise in treating pancreatic and colorectal cancers in patients with KRAS mutations. The study found that the vaccine significantly decreased tumor biomarkers and produced strong T-cell responses, leading to a reduced risk of relapse and death.
A new type of cell therapy has shown promising results in improving survival rates and reducing pneumonia among critically ill ARDS patients recovering from severe Covid-19. The invariant natural killer T (iNKT) cell therapy, known as agenT-797, triggered an anti-inflammatory response and activated anti-viral immunity.
La Jolla Institute researchers discovered that prior exposure to a common cold coronavirus partially protects mice from lung damage during a subsequent SARS-CoV-2 infection. Harnessing 'cross-reactive' T cells may lead to novel vaccines with broad, pan-coronavirus protection.
Research reveals memory T cells formed after Omicron breakthrough infection provide enhanced immunity against future variants. The study suggests the immune system adapts to combat emerging strains, leading to higher chances of inducing memory T cell defenses.
Researchers have revealed CD4+ T cells can work effectively on their own to control melanoma, challenging conventional understanding. Harnessing their potential therapeutically holds great promise for improving current cancer immunotherapies.
A subset of CD4+ 'helper' T cells helps fight cytomegalovirus infection and reduces the chances of transmission. The late-rising T cells expand long after the initial response has died down, gathering in high numbers in the salivary gland.
Researchers found that intradermal administration of the JYNNEOS smallpox vaccine induces an efficient immune response, protecting people living with HIV from contracting the monkeypox virus. Individuals with low CD4 T cell levels require a booster dose to compensate for their immunosuppressed status.
Researchers at Duke-NUS Medical School have discovered a potential intranasal vaccine candidate that provides improved, longer-lasting immunity against COVID-19. The vaccine boosts mucosal antibody response and enhances long-term immune protection through preferential induction of airway-resident T cells and central memory T cells.
Researchers found that vaccinated B cell-deficient individuals have a robust T cell response to SARS-CoV-2, despite lack of anti-spike antibodies, resulting in markedly reduced rates of hospitalization and severe COVID-19. This study provides reassuring evidence for immunocompromised patients to get vaccinated.
A new study suggests that stronger responses from immune cells called CD8+ T cells may be key to increasing HIV immunity. Future HIV vaccine candidates may benefit from additional doses or longer persistence in the body to further stimulate the immune system.
Researchers at La Jolla Institute for Immunology found that most T cells can still target epitopes on the new Pirola variant, suggesting people may be able to mount a response against it. The study's findings provide positive news in the fight against SARS-CoV-2, emphasizing the importance of vaccination with updated vaccines.